Atypical hemolytic uremic syndrome (aHUS) is a rare disease in pediatrics with 6-10% of cases associated with complement factor H autoantibodies<i>.</i> Ravulizumab is a new treatment option available for long-term management through blockage of the terminal complement cascade. Here, CFH is linked to atypical hemolytic-uremic syndrome.